Q-omics provides the consensus-scored LINC01350 profile across patient tissues and cancer cell-line models. LINC01350 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LINC01350 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, LINC01350 RNA expression shows 6,431 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, KICH, and STAD as cancer lineages where LINC01350 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01350 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01350 survival associations across molecular data types. LINC01350 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01350 RNA expression–survival associations across cancer types. High LINC01350 expression shows unfavorable associations in CHOL, KIRP, ACC, SKCM, PAAD and ESCA. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CHOL as the clearest survival context for LINC01350 RNA expression.
This table summarizes LINC01350 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01350. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01350 shows lower tumor expression in KICH and KIRC and higher tumor expression in UCEC and LUSC. The KICH box plot shows higher LINC01350 RNA expression in normal versus tumor tissue (log2 FC = −0.124, t-test p < 0.001).
This table shows molecular features associated with LINC01350 in patient tissues and cancer cell lines. In patient samples, LINC01350 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
